ABOUT CAMURUS PRODUCTS PIPELINE TECHNOLOGIES INVESTORS MEDIA CONTACT ENGLISH DEVELOPMENT PIPELINE A strong and diversified pipeline Camurus' clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. PHARMACEUTICALS CAM2029 RARE ENDOCRINE DISORDERS Improving treatment for patients with acromegaly and NET Somatostatin analogues are the mainstay of medical therapy for patients with acromegaly, and for the effective symptom control in patients with neuroendocrine tumors (NET). CAM2029 is developed for the treatment of acromegaly and neuroendocrine tumors. The product candidate offers important potential advantages over current marketed products, including easy administration, significantly increased bioavailability, and potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects. CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus' proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients’ themselves. CAM2029 – Key target attributes • Subcutaneous long-acting octreotide • Fast onset and one month duration of therapeutic plasma-levels • Provided ready-for-use in prefilled syringes for easy self-administration • Compatible with autoinjectors • High bioavailability – 500% higher than Sandostatin® LAR®, with potential for better treatment effects in some patients CAM2029 - Key publications Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study Pavel M, Borson‑Chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D., Cancer Chemotherapy and Pharmacology (2019) 83:375–385 Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF1 suppression to octreotide LAR in healthy volunteers Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Prakash Tripathi A, Linden M, Br J Clin Pharmacol (2015) 80:460-472 CAM2038 CHRONIC PAIN Round-the-clock relief from chronic pain Chronic pain is a global health problem, causing deterioration in general health, reduced quality of life, decreased work capacity and dependence and misuse of strong opioids. CAM2038 includes two long-acting subcutaneous buprenorphine investigational products for treatment of chronic pain. The product candidates are based on Camurus' proprietary FluidCrystal® injection depot technology and are intended for either weekly (q1w) or monthly (q4w) administration, each in multiple doses, to allow individualized treatment of patients with chronic pain. CAM2038 is aimed for providing round-the-clock pain relief, while decreasing the risks of respiratory depression and fatal overdoses associated with full µ-opioid agonists, such as morphine, oxycodone and fentanyl. The properties of CAM2038 are considered to conform to the targeted properties and to the guidelines and recommendations for treatments of chronic pain, i.e. the combination of long lasting efficacious analgesia with a reduced risk of misuse, abuse and illicit diversion. CAM2038 – Key target attributes • Round-the-clock pain relief • Dose-proportional long-term buprenorphine exposure • Improved treatment adherence • Reduced number of administrations • Reduced risk of misuse, abuse and diversion • Reduced risk of overdose compared with full µ-opioid receptor agonists • Classified as Schedule 3 drug by the US DEA, with moderate to low risk of dependence CAM2032 PROSTATE CANCER Easy and convenient long-acting treatment of prostate cancer Hormone therapies for prostate cancer using gonadotropin-releasing hormone agonists such as leuprolide, are established therapies aimed at reducing the level of testosterone and thereby impeding the growth of cancer cells. CAM2032 is a long-acting subcutaneous leuprolide investigational product for treatment of prostate cancer. Additional potential indications for CAM2032 include precocious puberty, gender identity disorders, and endometriosis. The product candidate is based on Camurus’ FluidCrystal® injection depot technology and will be provided as a prefilled syringe requiring no reconstitution or conditioning. CAM2032 is being developed for easy subcutaneous injection by patients themselves in the form of a small volume injection with a duration of one month. CAM2032 – Key target attributes • Convenient self-administration • Long-acting duration • Small injection volume and thin injection needle (27G) • Compatible with autoinjectors • Manufacturing by standard processes Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Ideongatan 1A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations ir@camurus.com ABOUT CAMURUS PRESENTATIONS PIPELINE PRODUCTS TECHNOLOGIES INVESTORS CAREER LEGAL NOTICE PRIVACY CONTACT IR CONTACT By continuing to use the site, you agree to the use of cookies. more information Accept